Bardi Francesca, Moccia Lorenzo, Kotzalidis Georgios D, Boggio Gianluca, Brugnami Andrea, Sfratta Greta, Janiri Delfina, Sani Gabriele, Simonetti Alessio
Department of Neurosciences, Section of Psychiatry, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy.
Department of Neuroscience, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy.
Healthcare (Basel). 2025 Jul 16;13(14):1709. doi: 10.3390/healthcare13141709.
: Long-acting injectable antipsychotics (LAIs) represent a significant advancement in the treatment of schizophrenia (SCZ), particularly for improving adherence and long-term outcomes. This study aimed to assess the clinical outcomes of patients receiving atypical LAIs compared to those on various oral antipsychotics over a one-year follow-up in a naturalistic setting. : Sixty patients with SCZ were subdivided in two groups, those receiving LAIs ( = 25) and those receiving oral antipsychotics ( = 35). The groups were comparable for age, gender, educational attainment, employment status, marital status, smoking habits, and baseline SCZ severity, with no differences in baseline chlorpromazine equivalent dosages. : Over the follow-up period, patients in the LAI group discontinued treatment less frequently ( = 4.72, = 0.030), showed fewer suicide attempts ( = 5.63, = 0.018), fewer hospitalizations ( = 4.95, = 0.026), and fewer relapses ( = 6.61, = 0.010). Significant differences also emerged on the Drug Attitude Inventory (DAI-10) scores (F = 8.76, = 0.005) and Body Mass Index (BMI) values (F = 8.32, = 0.007), with the LAI group showing more favorable outcomes. : LAIs, compared to oral antipsychotics, may promote treatment adherence, as shown by decreased hospitalization; furthermore, their use is related with better outcomes, like fewer relapses and less suicide attempts in individuals with SCZ in real-world settings.
长效注射用抗精神病药物（LAIs）是精神分裂症（SCZ）治疗领域的一项重大进展，尤其有助于提高依从性和改善长期预后。本研究旨在评估在自然环境下接受非典型LAIs治疗的患者与接受各种口服抗精神病药物治疗的患者在一年随访期内的临床结局。：60例SCZ患者被分为两组，一组接受LAIs治疗（n = 25），另一组接受口服抗精神病药物治疗（n = 35）。两组在年龄、性别、教育程度、就业状况、婚姻状况、吸烟习惯和基线SCZ严重程度方面具有可比性，基线氯丙嗪等效剂量无差异。：在随访期间，LAIs组患者的治疗中断频率较低（χ² = 4.72，P = 0.030），自杀未遂次数较少（χ² = 5.63，P = 0.018），住院次数较少（χ² = 4.95，P = 0.026），复发次数较少（χ² = 6.61，P = 0.010）。药物态度量表（DAI - 10）评分（F = 8.76，P = 0.005）和体重指数（BMI）值（F = 8.32，P = 0.007）也出现了显著差异，LAIs组显示出更有利的结局。：与口服抗精神病药物相比，LAIs可能会提高治疗依从性，表现为住院次数减少；此外，在现实环境中，LAIs的使用与更好的结局相关，如SCZ患者复发次数减少和自杀未遂次数减少。
